We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Bacillus sp. DU‐106 ameliorates type 2 diabetes by modulating gut microbiota in high‐fat‐fed and streptozotocin‐induced mice.
- Authors
Yan, Jing; Li, Junjian; Xue, Qiuyan; Xie, Shiqing; Jiang, Jinjin; Li, Pan; Du, Bing
- Abstract
Aims: Type 2 diabetes (T2D) is a chronic disease that manifests as endocrine and metabolic disorders that seriously threatening public health. This study aimed to investigate the effects of Bacillus sp. DU‐106 on anti‐diabetic effects and gut microbiota in C57BL/6J mice fed a high‐fat diet and streptozotocin‐induced T2D. Methods and Results: Bacillus sp. DU‐106 was administered to model mice for eight consecutive weeks. Oral administration of Bacillus sp. DU‐106 decreased food and water intake and alleviated body weight loss. Moreover, Bacillus sp. DU‐106 imparted several health benefits to mice, including balanced blood glucose, alleviation of insulin resistance in T2D mice and an improvement in lipid metabolism. Furthermore, Bacillus sp. DU‐106 protected against liver and pancreatic impairment. Additionally, Bacillus sp. DU‐106 treatment reshaped intestinal flora by enhancing gut microbial diversity and enriching the abundance of certain functional bacteria. Conclusion: Collectively, these findings suggest that Bacillus sp. DU‐106 can ameliorate T2D by regulating the gut microbiota. Significance and Impact of Study: Therefore, a novel probiotic, Bacillus sp. DU‐106 may be a promising therapeutic agent for improving and alleviating T2D in mice.
- Subjects
BACILLUS (Bacteria); TYPE 2 diabetes; GUT microbiome; STREPTOZOTOCIN; ORAL drug administration
- Publication
Journal of Applied Microbiology, 2022, Vol 133, Issue 5, p3126
- ISSN
1364-5072
- Publication type
Article
- DOI
10.1111/jam.15773